Neoadjuvant chemotherapy is being increasingly used in the treatment of breast carcinoma. We performed a single-center retrospective analysis of the results of neoadjuvant therapy in 376 breast carcinoma patients treated with three different regimens combining doxorubicin and paclitaxel (AT), dose-dense doxorubicin and cyclophosphamide with sequential weekly paclitaxel (DD AC-P), or the combination of trastuzumab with chemotherapy (DD AC-PT). The expression of estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor receptor (HER)-2 was determined immunohistochemically. Pathological response was determined in 318 patients. Pathological complete response (pCR) was observed in 18% of patients. The pCR rate was significantly higher in patients treated with DD regimen (22 vs. 13%) and younger than 55 years (23 vs. 13%). The pCR rate was higher in patients with triple negative (TN) tumors (43%) and tumors over-expressing HER-2 (HER-2+; 28%) compared to patients with ER- or PR-positive tumors not expressing HER-2 (ER/PR+HER-2-; 6%). In patients with TN tumors pCR rate was significantly higher after treatment with DD AC-P compared to AT (61 vs. 22%, p=0.005). pCR was associated with significantly improved relapse-free survival (RFS) and overall survival (OS), but when analysis was performed based on tumor phenotype, the difference was significant only in patients with TN tumors. In multivariate analysis, pCR, stage, and ER expression were significant predictors of RFS, while pCR, stage, ER and DD regimen were significant predictors of OS. In conclusion, present data indicate superiority of a DD regimen in obtaining pCR in patients with breast carcinoma treated with neoadjuvant chemotherapy. The difference in efficacy is due mostly to markedly higher pCR rate in patients with TN tumors.

Department of Oncology Palacký University Medical School and Teaching Hospital 1 P Pavlova 6 775 20 Olomouc Czech Republic

Zobrazit více v PubMed

Breast Cancer Res Treat. 2010 Dec;124(3):689-99 PubMed

J Clin Oncol. 2001 Nov 15;19(22):4224-37 PubMed

Breast Cancer Res Treat. 2010 Jan;119(2):315-23 PubMed

J Clin Oncol. 2005 Apr 20;23(12):2676-85 PubMed

Clin Cancer Res. 2005 Aug 15;11(16):5678-85 PubMed

Cancer. 2010 Mar 15;116(6):1431-9 PubMed

Am J Surg. 2009 Oct;198(4):520-5 PubMed

J Clin Oncol. 2005 Jun 1;23(16):3686-96 PubMed

N Engl J Med. 2005 Oct 20;353(16):1659-72 PubMed

J Natl Cancer Inst. 2005 Feb 2;97(3):188-94 PubMed

J Clin Oncol. 2009 Jun 20;27(18):2938-45 PubMed

Cancer J Sci Am. 1998 Mar-Apr;4(2):125-31 PubMed

Lancet. 2003 Aug 2;362(9381):362-9 PubMed

J Clin Oncol. 2003 Mar 15;21(6):976-83 PubMed

J Clin Oncol. 1999 Feb;17(2):460-9 PubMed

J Clin Oncol. 2005 Jun 1;23(16):3676-85 PubMed

Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10393-8 PubMed

Ann Surg Oncol. 2010 Sep;17(9):2411-8 PubMed

J Natl Cancer Inst. 2010 Dec 15;102(24):1845-54 PubMed

Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 PubMed

J Clin Oncol. 2003 Apr 15;21(8):1431-9 PubMed

Breast Cancer Res Treat. 2009 Feb;113(3):479-90 PubMed

J Clin Oncol. 1997 Jul;15(7):2483-93 PubMed

Clin Cancer Res. 2007 Apr 15;13(8):2329-34 PubMed

Br J Cancer. 2002 Apr 8;86(7):1041-6 PubMed

Anticancer Res. 2008 Jul-Aug;28(4C):2389-96 PubMed

Ann Oncol. 2011 Sep;22(9):1988-1998 PubMed

Cancer Invest. 2008 Dec;26(10):1024-31 PubMed

J Clin Oncol. 1998 Aug;16(8):2672-85 PubMed

J Clin Oncol. 2005 Sep 1;23(25):5983-92 PubMed

J Clin Oncol. 2006 Apr 20;24(12):1940-9 PubMed

Clin Cancer Res. 2004 May 15;10(10):3249-61 PubMed

J Clin Oncol. 2006 May 1;24(13):2019-27 PubMed

N Engl J Med. 2006 Feb 23;354(8):809-20 PubMed

J Clin Oncol. 2004 Jun 15;22(12):2294-302 PubMed

Am J Clin Oncol. 1993 Jun;16(3):223-8 PubMed

Br J Cancer. 2003 Feb 10;88(3):406-12 PubMed

Breast Cancer Res Treat. 2011 Jan;125(1):145-56 PubMed

N Engl J Med. 2002 Dec 19;347(25):1999-2009 PubMed

N Engl J Med. 2005 Oct 20;353(16):1673-84 PubMed

J Clin Oncol. 2008 Mar 10;26(8):1275-81 PubMed